Evidence map›Paper›PMID 40470159›Full record

ArticleERJ open research2025

Real-world improvement in ultra-low-dose thoracic computed tomography scores, systemic inflammatory markers and patient-reported outcome measures after elexacaftor/tezacaftor/ivacaftor treatment.

Hisham Ibrahim, Alexander T O'Mahony, Kevin F Deasy, Michael Waldron, Mairead McCarthy, James Dorgan, Claire Fleming, Ciara Howlett, Edel O'Riordan, Yvonne McCarthy and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hisham IbrahimCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Alexander T O'MahonyDepartment of Radiology, Cork University Hospital, Cork, Ireland.
Kevin F DeasyCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Michael WaldronDepartment of Radiology, Cork University Hospital, Cork, Ireland.
Mairead McCarthyCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
James DorganCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Claire FlemingCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Ciara HowlettCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Edel O'RiordanCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Yvonne McCarthyCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Sarah TwohigCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Janice MansfieldCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Tamara VaggCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Desmond M MurphyCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Paul O'ReganCystic Fibrosis Registry of Ireland, CF House, Dublin, Ireland.ORCID https://orcid.org/0009-0003-6072-1600
Laura KirwanCystic Fibrosis Registry of Ireland, CF House, Dublin, Ireland.
Joseph A EustaceThe HRB-funded Clinical Research Facility, University College Cork, Cork, Ireland.
Owen J O'ConnorDepartment of Radiology, Cork University Hospital, Cork, Ireland.
Michael M MaherCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.
Barry J PlantCork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Ireland.ORCID https://orcid.org/0000-0002-4611-6768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clinical trials with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis were associated with significant improvements in % predicted forced expiratory volume in 1 s (FEV Methods: In a real-world setting with 61 people with cystic fibrosis, we prospectively recorded FEV Results: Significant improvements in FEV Conclusion: ETI responders, demonstrate significant improvements in CT imaging, circulating cytokines and PROMs, which may be of further use evaluating cystic fibrosis transmembrane conductance regulator modulation treatment response.

Identifiers

PMID40470159
PMCPMC12134916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.